Answers are grounded in this paper and cite their sources.
Doravirine is a novel non‐nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus type 1 infection. Because of potential concomitant administration with acid‐reducing agents, a drug‐interaction trial was conducted to evaluate the potential impact of these types of medications on doravirine pharmacokinetics. In an open‐label, 3‐period, fixed‐sequence trial, healthy adult participants received the following: period 1, a single dose of doravirine 100 mg; period 2, coadministration of a single dose of doravirine 100 mg and an antacid (1600 mg aluminum hydroxide, 1600 mg magnesium hydroxide, and 160 mg simethicone); period 3, 40 mg pantoprazole once daily on days 1–5 coadministered with a single dose of doravirine 100 mg on day 5. There was a minimum 10‐day washout between periods. Plasma samples for pharmacokinetic evaluation were collected, and safety was assessed. Fourteen participants (8 male, 6 female) were enrolled, and 13 completed the trial. Geometric mean ratios (90% confidence intervals) for doravirine AUC0‐inf, Cmax, and C24 for doravirine + antacid/doravirine were 1.01 (0.92–1.11), 0.86 (0.74–1.01), and 1.03 (0.94–1.12), respectively, and for doravirine + pantoprazole/doravirine were 0.83 (0.76–0.91), 0.88 (0.76–1.01), and 0.84 (0.77–0.92), respectively. Doravirine was generally well tolerated administered alone or with either of the acid‐reducing agents. Coadministration of an aluminum/magnesium‐containing antacid or pantoprazole did not have a clinically meaningful effect on doravirine pharmacokinetics, supporting the use of acid‐reducing agents with doravirine.
No takes yet. Share an insight, caveat, or question.
Khalilieh et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: